Nuclear Radiology: Page 3

PET reveals patterns underlying cognitive decline in patients with DLB

F-18 FDG-PET imaging in patients with dementia with Lewy bodies (DLB) has shown that brain hypo- and hypermetabolism may have different affects on cognition.

January 5, 2024

DLB-hypo (hypometabolic changes in dementia with Lewy bodies) was characterized by relatively reduced bilateral metabolic activity (color-coded blue) in the bilateral parietal, temporal, and occipital cortices, while DLB-hyper (hypermetabolic changes in dementia with Lewy bodies) showed relatively increased metabolic activity (color-coded red) in the cerebellum, bilateral sensorimotor, orbitofrontal, insular, and parahippocampal cortices, bilateral putamen, globus pallidum, hippocampus, and amygdala. Image courtesy of npj Parkinson’s Disease.

FAPI-PET outperforms FDG-PET in diagnosing pancreatic cancer

F-18 FAPI-PET/CT is superior to F-18 FDG-PET/CT for diagnosing and staging patients with pancreatic cancer.

January 5, 2024

Typical PET (top), PET/CT (middle), and CT and MR (bottom) images of primary tumor obtained using both radiotracers in representative patients (A and B). Tumor is marked by arrows. DWI = diffusion-weighted imaging. Image courtesy of the Journal of Nuclear Medicine.

NorthStar and Curadh MTR enter strategic partnership

By AuntMinnie.com staff writers

NorthStar Medical Radioisotopes and Curadh MTR have entered a strategic collaboration agreement to develop radiopharmaceuticals.

January 3, 2024

PET/CT predicts brain tumors in melanoma patients

PET/CT scans have the potential to predict brain metastasis in melanoma patients.

January 3, 2024

A 49-year-old patient with primary clinical stage III melanoma underwent F-18 FDG-PET. The primary tumor Breslow thickness was 6.5 mm. On initial F-18 FDG-PET images, this patient had a high SUVmax (52), resulting in limited survival with the occurrence of brain metastasis in the first year of follow-up (horizontal arrow). Notably, during the course of the treatment, the patient underwent surgical removal of the primary tumor as well as lymph node dissection, followed by neoadjuvant radiotherapy and immunotherapy. Image courtesy of Cancers.

GT Medical Technologies inks supply deal with Perspective Therapeutics

By AuntMinnie.com staff writers

GT Medical Technologies has inked an agreement with Perspective Therapeutics to acquire all radioactive cesium-131 seed assets from its subsidiary Isoray Medical.

December 12, 2023

Businessman Shake Hand Collegue

Pneumonia on CT? Consider additional imaging so as not to miss cancer

By Kate Madden Yee

Pneumonia can hide underlying lung cancers, and repeat imaging with PET/CT should be considered in patients with high clinical suspicion of malignancy.

December 8, 2023

Lung Ct Images 400

ChatGPT tested on nuclear medicine cases

ChatGPT shows potential for diagnosing nuclear medicine cases, yet needs further development before it can be implemented in practice.

December 6, 2023

Telix highlights first patient dosed with new renal cancer PET agent

By AuntMinnie.com staff writers

Telix Pharmaceuticals is highlighting that the first patient has been dosed with the company's TLX250-CDx for clear cell renal cell carcinoma.

December 4, 2023

PET/CT predicts patient responses to CAR-T cell therapy

F-18 FDG-PET/CT scans may predict outcomes in patients with large B cell lymphoma undergoing chimeric antigen receptor (CAR) T-cell therapy.

December 4, 2023

Pet Ct Machine 400

Bayer reports results of phase II gadoquatrane clinical trial at RSNA

By AuntMinnie.com staff writers

Bayer presented positive results of its phase II clinical trial of macrocyclic gadolinium-based compound gadoquatraine in a scientific session at RSNA 2023.

November 28, 2023

Bayer Rsna 2019 400

PET tracer shows promise in prostate cancer patients

Gallium-68 RM2-PET/MRI is better than MRI alone for detecting relapse in prostate cancer patients, according to research presented at RSNA 2023.

November 26, 2023

An image showing potentially different sites of PET radiotracer uptake by prostate cancer tumors between U.S. approved Ga-68 PSMA-PET and experimental Ga-68 RM2. Image courtesy of Heying Duan, MD, Stanford University.

FAPI-PET shows promise for detecting pancreatic cancer

FAPI-PET imaging may become a powerful diagnostic tool for detecting pancreatic cancer.

November 20, 2023

A male patient with suspected recurrent pancreatic cancer. Contrast-enhanced CT shows mass around superior mesenteric artery after pancreatectomy. F-18 FDG only shows discrete uptake of lesion (SUVmax, 3.8), whereas Ga-68 FAPI clearly visualizes recurrent tumor. Patient received adjuvant chemotherapy after Ga-68 FAPI. Patient denied recommended chemotherapy. Increase of CA19-9 levels (from 240 U/mL to 767 U/mL) and follow-up imaging eight months later validated progression of mesenteric mass as well as increased F-18 FDG uptake (SUVmax, 5.3). Image courtesy of the Journal of Nuclear Medicine.

Page 3 of 81